{
    "nctId": "NCT00397761",
    "briefTitle": "Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer",
    "officialTitle": "Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Pathological complete response rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed infiltrating carcinoma of the breast or inflammatory breast cancer\n\n  * Stage II-IIIB disease (T1-4, N1-2, M0)\n* Previously untreated disease\n* Previously unresected disease\n* High-risk disease that is not resectable by lumpectomy alone\n* Any HER2/neu status (positive, negative, or unknown) allowed\n* Hormone receptor status:\n\n  * Any estrogen/progesterone status (positive, negative, or unknown) allowed\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy \\> 3 months\n* Absolute neutrophil count \\> 1,500/mm\u00b3\n* Platelet count \\> 100,000/mm\u00b3\n* Hemoglobin \\> 9.0 g/dL\n* Creatinine \\< 1.5 mg/dL\n* Bilirubin \\< 1.5 times upper limit of normal (ULN)\n* ALT and AST \\< 2.5 times ULN (5 times ULN if due to Gilbert's disease)\n* Alkaline phosphatase \\< 2.5 times ULN (5 times ULN if due to Gilbert's disease)\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}